AL amyloidosis in the Chilean public health system: a pending debt. Multicenter study of the Chilean Monoclonal Gammopathies Cooperative Group

CAMILA PEÑA1, JOSÉ TOMÁS GONZÁLEZ2, HERNÁN LÓPEZ-VIDAL3, JAVIERA DONOSO4, CAROLINA CONTRERAS5, CARMEN GLORIA VERGARA5, RICARDO HOJAS6, PABLO SOTO7, GONZALO CORREA8, RICARDO VALJALO8, ÁLVARO RÍOS8, JORGE LARRONDO9, JAIME ÁLVAREZ10, CHRISTINE ROJAS11

ABSTRACT

Background: Immunoglobulin light chain (AL) amyloidosis is a rare and underdiagnosed entity. Aim: To characterize patients with AL amyloidosis in Chilean public health centers. Material and Methods: We conducted a retrospective, multicenter study. Public centers of the Chilean Monoclonal Gammopathies Cooperative Group were asked to search for patients with AL amyloidosis in their databases. Epidemiological, clinical and laboratory characteristics were evaluated. Results: Forty-two patients aged 22 to 84 years were found. Twenty four percent had localized AL amyloidosis; 64% had a lambda light chain clone; 47% were associated with multiple myeloma and 9% with non-Hodgkin lymphoma. The most commonly involved organ was the kidney (76%). Serum free light chains were measured in 31% and an echocardiogram was performed in 74% of patients. Seventeen percent of patients received only palliative care, 17% were treated with bortezomib, 21% with thalidomide, and 40% with melphalan. No patient was transplanted. The mean overall survival (OS) of the group was 19 months. The 5-year OS was 28%. Conclusions: It is important to obtain these realistic, national data to initiate strategies to improve early diagnosis and proper management of this disease.

(Rev Med Chile 2019; 147: 1239-1246)

Keywords: Amyloidosis; Bortezomib; Multiple Myeloma; Paraproteinemias; Transplantation.

Amiloidosis AL en el sistema público de Chile: una deuda pendiente. Estudio multicéntrico

La amiloidosis AL es una entidad poco frecuente y subdiagnosticada. Mientras todo el mundo discute sobre las nuevas herramientas diagnósticas y terapéuticas, en Chile y en América Latina en general, estamos lejos de esa realidad. El objetivo del presente estudio fue caracterizar a los pacientes con amiloidosis AL en centros del sistema público de nuestro país. Se realizó un estudio retros-
Amyloidosis is a rare and underdiagnosed entity, where pathogenic monoclonal light chains are produced by a small clone of plasma cells or, rarely, by a mature B cell clone. These pathogenic proteins undergo a conformational change which renders them insoluble, favoring their deposition in tissues and eventually organ malfunction. Amyloidosis has an estimated incidence of 3-14/1 million inhabitants/year, depending on the geographical area.

While the whole world discusses about the new diagnostic and therapeutic tools, in Chile, and Latin America in general, we are far from that reality. There is little information about AL amyloidosis in Chile, consisting mainly on case reports. The largest report was in 2005, where 11 cases were described.

The aim of the present study is to characterize patients with AL amyloidosis in public health centers throughout the country.

Materials and Methods

We conducted a retrospective, descriptive, multicenter study. Cases were collected between 2010 and 2018. The public centers are members of the Chilean Monoclonal Gammapathies Cooperative Group, they were asked to search in their databases to look for patients diagnosed with AL amyloidosis. In all centers, the diagnosis of AL amyloidosis was made with a positive Congo red stain on tissue biopsy. Affected organs were determined by biopsy or according to the definition of Gertz et al. Epidemiological, clinical and laboratory characteristics were evaluated.

A descriptive statistical analysis was done. Overall survival (OS) was calculated with Kaplan Meier curves and a comparison was made with log Rank test.

The present study was approved by the corresponding Ethics Committee.

Results

Data was collected from 42 patients of eight public health centers. The main characteristics are detailed on Table 1. The median age was 65 years, ranging from 22 to 84 years. The male to female ratio was 1:0.75. Twenty four percent were diagnosed as localized AL amyloidosis; paraprotein was found in all the patients, and 64% presented with a lambda light chain clone; 47% of cases were associated with multiple myeloma (MM), and 9% with non-Hodgkin lymphoma (NHL) (Figure 1), 2 MALT lymphomas, 1 lymphoplasmacytic lymphoma, and a non-characterized low grade B cell lymphoma. The most frequently involved organ was the kidney (76%). The serum free light chain (SFLC) was performed in 31% and the echocardiogram in 74%. The 17% received only palliative care, 17% received treatment with bortezomib, 21% with talidomide and 40% with melphalan. No patient was transplanted. The median overall survival (OS) of the group was 19 months. The OS at 5 years was 28%.
Table 1. Patient’s characteristics and analysis by group: primary AL amyloidosis, MM-associated AL amyloidosis and NHL-associated AL amyloidosis (p < 0.5)

|                                | Total (n = 42) | Primary amyloidosis (n = 18) | MM-associated (n = 20) | NHL-associated (n = 4) | p value |
|--------------------------------|----------------|------------------------------|------------------------|------------------------|---------|
| Male, n (%)                    | 24 (47)        | 11 (61)                      | 12 (60)                | 1 (25)                 | NS      |
| Median age, years (range)      | 65 (22-84)     | 58 (33-84)                   | 65 (22-77)             | 63 (56-77)             | NS      |
| iFLC= Lambda, n (%)            | 27 (64)        | 12 (67)                      | 13 (65)                | 2 (50)                 | NS      |
| iFLC= Kappa, n (%)             | 13 (31)        | 5 (28)                       | 7 (35)                 | 1 (25)                 | NS      |
| Heavy chain only, n (%)        | 2 (5)          | 1 (5)                        | 0 (0)                  | 1 (25)                 | NS      |
| Localized involvement, n (%)   | 10 (24)        | 5 (28)                       | 3 (15)                 | 2 (50)                 | NS      |
| Multi-organ involvement, n (%) | 32 (76)        | 13 (72)                      | 17 (85)                | 2 (50)                 | NS      |
| Cardiac involvement, n (%)     | 20 (48)        | 10 (56)                      | 10 (50)                | 0 (0)                  | NS      |
| Renal involvement, n (%)       | 32 (76)        | 14 (78)                      | 17 (85)                | 1 (25)                 | NS      |

NS: not significant.

Figure 1. Frequency of primary AL amyloidosis and associated AL amyloidosis.

Figure 2. Frequency of affected organs in the studied patients.

The kidney (76%), followed by the heart (48%) (Figure 2). The analysis by group: 1.- Primary amyloidosis, 2.- MM-associated amyloidosis, and 3.-NHL-associated AL amyloidosis showed no statistical difference between them (Table 1).

Regarding diagnostic tests (Figure 3), 100% reported having performed serum protein electrophoresis (sPEP), 69% serum immunofixation (sIFE) and 43% urine IFE. Serum free light chains (sFLC) were performed in 31% of the patients.

Heart involvement by echocardiogram was looked for in 74%, and renal involvement was screened in 98%.

As seen in Table 2, the most frequently performed biopsies were bone marrow (52%) and...
subcutaneous fat tissue (38%), being these samples diagnostic in 45% and 44% of cases, respectively. Renal biopsy was performed in 33% of the cases, with a positive diagnosis in all of them.

Treatment was heterogeneous: 17% were treated with bortezomib based therapy, 21% with cyclophosphamide, thalidomide, and dexamethasone (CTD), 40% with melphalan based therapy, and 17% received only palliative care. No patient received a bone marrow transplant.

The median OS of the group was 19 months. The 3-year OS was 38%, and the 5-year OS 28% (Figure 5). There was no survival difference between patients with or without associated MM (5-yr OS of 22% vs 24%; p = 0.8), with or without use of novel agents (5-yr OS of 15% vs 38%; p = 0.09), localized versus systemic amyloidosis (5-yr OS of 36% vs 27%; p = 0.6) or with or without cardiac involvement (5-yr OS of 25% vs 31%; p = 0.31).
Discussion

This is to our knowledge, the larger experience published in Chile and Latin-America on this topic.

The scarce number of patients may be due to registry deficiency in our healthcare system. This is further favored by lack of clinical suspicion and reduced access to diagnostic tools.

Epidemiological and clinical characteristics

The demographic and clinical characteristics proved to be similar to what is reported in the international literature. The disease is more frequent in men, and the median age is approximately 65 years, according to series carried out in America, Europe and Asia11-13.

Half of our patients were MM-associated, when the described rate is between 10-15%. This may be attributed to the fact that the MM-amyloidosis association is well known by general physicians, and therefore, more often suspected and diagnosed.

In 5% to 7% of patients, AL amyloidosis is associated with an underlying IgM secreting lymphoma, usually lymphoplasmocytic and MALT type14. In our cohort we found 10%. Compared with patients who have non-IgM AL amyloidosis, these patients are described to be older, having a higher prevalence of neuropathy and lymph node involvement, and a lower proportion of cardiac involvement. This was not demonstrated in this study, most likely due to the low number of recruited patients.

Twenty four percent of patients were catalogued as localized AL amyloidosis. Much more than described in literature. The lack of complete organ involvement study might explain this result.

The most frequent light chain reported is lambda, in about 80% of patients. Our cohort was not the exception, although it was observed in only 64% of the patients. One explanation could be the high percentage of MM-associated AL amyloidosis in our cohort.

The most affected organs were the kidney, followed by the heart, which coincides with other series11-13. The results obtained regarding affected organs must be analyzed with caution, since not all the patients had a complete organ study. For example, 26% of patients did not have an echocardiogram performed, despite cardiac involvement is the most frequently reported.

As described, the most characteristic signs such as macroglossia and periorbital purpura were found in a small number of patients (26% and 7%, respectively).

Screening

Appropriate screening should include sIFE15, urine IFE16, and sFLC assay17. In a recent survey conducted by our group, it was observed that only a small percentage of public health centers have these three studies available (not published). This is a serious concern and partially explains the underdiagnoses of this disease in our country.

Diagnosis

For an accurate diagnosis, the standard recommendation is to perform a biopsy/aspiration of subcutaneous fat and a bone marrow (BM) biopsy18,19, which would have a sensitivity of 85%11-20. This was not consistent with the results of our study, where the sensitivity of subcutaneous fat and BM biopsies was low, confirming the diagnosis in less than half of the cases. Larger studies are required to verify this low sensitivity of the standard anatomopathological recommended studies. Experienced pathologists are important for an accurate diagnosis, and it is a factor to take into consideration when analyzing the results of this study.

In the majority of cases, the diagnosis of AL amyloidosis was made only after biopsy of the affected organ was performed, which suggests a low level of suspicion of AL amyloidosis prior to the biopsy. Although biopsy of the affected organ increases sensitivity to 95%, being 100% in the case of renal biopsy in our cohort, this procedure should be indicated with caution due to its invasive nature.

Unequivocal amyloid typing using mass spectrometry in specialized laboratories is the basis for accurate diagnosis and subsequent treatment22,23. This technology is not available in Chile, where diagnosis relies on tissues testing positive to Congo red and immunohistochemical study. This also means that we cannot exclude other type of amyloidosis in our patients.

Prognosis

New biomarkers are currently being used for diagnosis, prognosis and follow-up. One of them
is the measure of sFLC\textsuperscript{24}. In 2003, Palladini et al. described the sensitivity of NT-proBNP in diagnosis and prognosis for the first time\textsuperscript{25}.

The Mayo Clinic score is the main tool used to define prognosis\textsuperscript{26,27}. In this score the NT-proBNP, troponin I and the difference of the involved light chain with the non-involved free light chain are included.

There is not enough data to evaluate prognosis in our studied patients, due to the lack of these markers in most of our centers.

**Treatment**

Unfortunately, the Chilean public health system has few treatment options. The current protocol continues being melphalan and dexamethasone, with no access to new drugs such as bortezomib. Although 17% of the patients were treated with bortezomib, the acquisition of this drug required cumbersome and time-consuming requests from each institution.

It is necessary to include bortezomib in our therapeutic arsenal as it is the drug that changed the vision of AL amyloidosis, demonstrating an excellent response of up to 71% complete response with cyclophosphamide-bortezomib-dexamethasone (CyBorD)\textsuperscript{28,29}. Another effective treatment is BMDex (bortezomib, melphalan and dexamethasone), which has shown very good results, superior to CyBorD in patients with high tumor burden\textsuperscript{30,31}. Moreover, a recent phase 3 study demonstrated a greater hematological and organ response with BMDex versus MDex\textsuperscript{32}. This positive outcome may be due to a proven high sensitivity of the plasma cells to bortezomib\textsuperscript{33}.

There are new pharmacological treatments which are unattainable in our country at this time, which include studies with carfilzomib, ixazomib, daratumumab and even anti-fibril antibodies\textsuperscript{34-36}.

**Autologous stem cell transplantation**

The introduction of autologous stem cell transplantation (ASCT) marked a major advance in the treatment of AL amyloidosis\textsuperscript{37} as it has improved OS through the years with a 5-year OS up to 77% and a reduction in mortality at 30 and 100 days of 3% and 5%, respectively\textsuperscript{38}. One study of 629 patients showed ~ 35% of patients obtaining complete remission and a median survival approaching up to 8 years\textsuperscript{39}. Unfortunately, the bone marrow transplant program in the Chilean public health system is restricted, and amyloidosis is not currently an indication of it, which explains why no patient had bone marrow transplant in our registry. Furthermore, there is just one report in Chile of 6 AL amyloidosis patients with bone marrow transplant\textsuperscript{40}.

**Survival**

Survival has doubled worldwide in the last decade; 30 to 40% of patients are now surviving more than 10 years\textsuperscript{32}. In Sweden, the median survival after diagnosis of AL amyloidosis is 3 years\textsuperscript{41}. The results in Chile are far below this, with a median OS of less than 20 months, which requires further analysis of the situation. It seems that physicians often do not suspect this disease on time, leading to a delay in the diagnosis. It is also necessary to optimize and standardize the diagnostic tools in all public health centers where amyloidosis is treated. In addition, the therapeutic resources are currently also insufficient.

Continuous education regarding this pathology is peremptory, as the most important step to avoid underdiagnoses is the awareness of this disease\textsuperscript{42}. An online survey from the Amyloid Research Consortium indicates that 37% of patients are not diagnosed until one year after the onset of initial symptoms, and an average of three medical appointments. Moreover, despite advances in therapeutic treatments, the frequency of sudden death within \( \leq 90 \) days of diagnosis remains at 25% -30%\textsuperscript{43}. Early detection can prevent cardiac damage and potentially reduce the risk of sudden death.

This study is limited by its retrospective nature, and small number of patients. In addition, data could not be obtained from all national public health centers nor was the requested data complete in all cases. Nevertheless, this is the reality in Chile and it is our belief that this initial report is necessary to generate a change.

**Conclusion**

There are shortfalls in the diagnostic study and treatment of AL amyloidosis in our public health centers. It is important to obtain realistic, national results to initiate strategies to improve both early diagnosis and management of this pathology. Improving awareness is therefore crucial.
Acknowledgments: To all the hematologists of the Chilean public health system who worked hard to collect all the data reported here.

References

1. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, et al. Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 2014; 21 (4): 221-4.
2. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006; 108 (8): 2520-30.
3. Dispenzieri A, Gertz MA, Buadi F. What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood Rev 2012; 26 (4): 137-54.
4. Bhat A, Selmi C, Naguwa SM, Cheema GS, Gershwin ME. Currents concepts on the immunopathology of amyloidosis. Clin Rev Allergy Immunol 2010; 38: 97-106.
5. Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O’Fallon WM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992; 79 (7): 1817-22.
6. Hemminki K, Li X, Forsti A, Sundquist J, Sundquist K. Incidence and survival in nonhereditary amyloidosis in Sweden. BMC Public Health 2012; 12: 974.
7. Berrios M, Armas-Merino R, Franco C, Parrochia E, Wolff C. Insuficiencia hepática aguda en amiloidosis hepática asociada a mieloma múltiple. Caso clínico. Rev Med Chile 2003; 131: 1301-4.
8. Peña C, Intriglio M, Gray AM, Cabrera ME. Amyloidosis extrema asociada a mieloma múltiple e insuficiencia renal terminal. Caso clínico. Rev Med Chile 2011; 139: 1471-4.
9. Palma CL, Grünholz D, Osorio G. Amiloidosis. Comunicación de 11 casos y revisión de la literatura. Rev Med Chil 2005; 133: 655-61.
10. Gertz MA, Comenzo R, Falk RH, Fermand JP, Ha zenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79 (4): 319-28.
11. Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005; 1753 (1): 11-22.
12. Muchtar E, Gertz MA, Kumar SK, Lacy MQ, Dingli D, Buadi FK, et al. Improved outcomes for newly diagnosed AL amyloidosis over the years 2000-2014: cracking the glass ceiling of early death. Blood 2017; 129 (15): 2111-9.
13. Shimazaki C, Hata H, Iida S, Ueda M, Katoh N, Sekijima Y, et al. Nationwide Survey of 741 Patients with Systemic Amyloid Light-chain Amyloidosis in Japan. Intern Med 2018; 57 (2): 181-7.
14. Sachchithanantham S, Roussel M, Palladini G, Klersy C, Mahmood S, Venner CP, et al. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis. J Clin Oncol 2016; 34 (17): 2037-45.
15. Katzmann JA. Screening panels for monoclonal gammopathies: Time to change. Clin Biochem Rev 2009; 30: 105-11.
16. Shaheen SP, Levinson SS. Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect. Clin Chim Acta 2009; 406: 162-6.
17. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23: 215-24.
18. Fernández de Larrea C, Verga L, Morbini P, Klersy C, Lavatelli F, Foli A, et al. A practical approach to the diagnosis of systemic amyloidosis. Blood 2015; 125 (14): 2239-44.
19. Miyazaki K, Kawai S, Suzuki K. Abdominal subcutaneous fat pad aspiration and bone marrow examination for the diagnosis of AL amyloidosis: the reliability of immunohistochemistry. Int J Hematol 2015; 102 (3): 289-95.
20. Nilsson KP, Ikenberg K, Aslund A, Fransson S, Kon radsson P, Röcken C, et al. Structural typing of systemic amyloidosis by luminescent-conjugated polymer spectroscopy. Am J Pathol 2010; 176 (2): 563-74.
21. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32 (1): 45-59.
22. Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood 2016; 128 (2): 159-68.
23. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009; 114 (24): 4957-9.
24. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains
ARTÍCULOS DE INVESTIGACIÓN

AL amyloidosis in Chilean public health system - C. Peña et al

in serum and urine. Clin Chem 2001; 47 (4): 673-80.

25. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107 (19): 2440-5.

26. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22 (18): 3751-7.

27. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012; 30 (36): 4541-9.

28. Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, et al. Efficacy and safety of once weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood 2011; 118 (4): 865-73.

29. Mikhaljov JR, Schuster SR, Jiménez-Zepeda VH, Bello N, Spong J, Reeder CB, et al. Cyclophosphamide bortezomib- dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012; 119 (19): 4391-4.

30. Palladini G, Milani P, Foli A, Vidus Rosin M, Basset M, Lavatelli F, et al. Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients. Leukemia 2014; 28 (12): 2311-6.

31. Venner CP, Gillmore JD, Sachchithanantham S, Mahmood S, Lane T, Foard D, et al. A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Leukemia 2014; 28 (12): 2304-10.

32. Kastritis E, Leleu X, Arnulf B, Zamagni E, Cibèira MT, Kwok F, et al. A randomized phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with AL amyloidosis [abstract]. Blood 2016; 128 (22).

33. Oliva L, Orfanelli U, Resnati M, Raimondi A, Orsi A, Milan E, et al. The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity. Blood 2017; 129 (15): 2132-42.

34. Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Selin DC, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood 2017; 130 (5): 597-605.

35. Kaufman GP, Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedlke M. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood 2017; 130 (7): 900-2.

36. Richards DB, Cookson LM, Berges AC, Barton SV, Lane T, Ritter JM, et al. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med 2015; 373 (12): 1106-14.

37. Comenzo RL, Vosburgh E, Simms RW, Bergethon P, Sarnacki D, Finn K, et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one year follow-up in five patients. Blood 1996; 88 (7): 2801-6.

38. D’Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research Study. J Clin Oncol 2015; 33 (32): 3741-9.

39. Sanchorawala V, Sun F, Quillen K, Sloan JM, Berk JL, Seldin DC. Long term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood 2015; 126 (20): 2345-7.

40. Sarmiento M, Lira P, Ocqueteau M, Rodriguez MA, Garcia MJ, Jara V, et al. Experiencia de 22 años de trasplante autólogo de células hematopoyéticas en pacientes con mieloma múltiple o amiloidosis sistémica. 1992-2014. Rev Med Chile 2014; 142 (12): 1497-501.

41. Hemminki K, Li X, Forsti A, Sundquist J, Sundquist K. Incidence and survival in nonhereditary amyloidosis in Sweden. BMC Public Health 2012; 12: 974.

42. Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium. Adv Ther 2015; 32: 920-8.